Publications by authors named "Hazel Weir"

Claim this Profile
T
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Agostina Nardone, Hazel Weir, Oona Delpuech, Henry Brown, Carmine De Angelis

Br J Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER/HER2 Advanced Breast Cancer.
Erika P Hamilton, Manish R Patel, Anne C Armstrong, Richard D Baird, Komal Jhaveri, Hazel M Weir

Clin Cancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Amir Bahreini, Zheqi Li, Peilu Wang, Kevin M Levine, Nilgun Tasdemir, Hazel M Weir

Breast Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating Mutations Differentially Affect the Efficacy of ER Antagonists.
Weiyi Toy, Hazel Weir, Pedram Razavi, Mandy Lawson, Anne U Goeppert

Cancer Discov· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Brendon Ladd, Anne Marie Mazzola, Teeru Bihani, Zhongwu Lai, James Bradford, Hazel M Weir

Oncotarget· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Hazel M Weir, Robert H Bradbury, Mandy Lawson, Alfred A Rabow, David Buttar

Cancer Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
Chris De Savi, Robert H Bradbury, Alfred A Rabow, Richard A Norman, Camila de Almeida, Hazel M Weir

J Med Chem· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
David W Jenkins, Sarah Ross, Margaret Veldman-Jones, Ian N Foltz, Brandon C Clavette, Hazel M Weir

Mol Cancer Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.
Jane Kendrew, Cath Eberlein, Brad Hedberg, Karen McDaid, Neil R Smith, Hazel M Weir

Mol Cancer Ther· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Clifford D Jones, David M Andrews, Andrew J Barker, Kevin Blades, Kate F Byth, Hazel M Weir

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
Malcolm Anderson, David M Andrews, Andy J Barker, Claire A Brassington, Jason Breed, Hazel M Weir

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
M Raymond V Finlay, David G Acton, David M Andrews, Andrew J Barker, Michael Dennis, Hazel M Weir

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis